Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:57:08.733Z.
Consensus retrieved: 2026-10-06T13:42:40.550Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:57:08.733Z.
Quote observation: 2026-10-06T15:55:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 880033b02c1352d2eede0b9825b135807cf5616a7da0006e335be03a15b23327
Forward PE Ratio (N/A) = Dated Quote Price ($12.58) / Consensus Forward EPS ($-0.86)
FORWARD PE RATIO
N/A
908 Devices Inc.
Market Cap
$516.21M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| 908 Devices Inc. (MASS) | $516.21M | N/A |
| Altimmune, Inc. (ALT)vs › | $520.33M | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $521.25M | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $523.17M | N/A |
| Allogene Therapeutics, Inc. (ALLO)vs › | $505.65M | N/A |
| Oculis Holding AG (OCS)vs › | $498.89M | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $535.31M | N/A |
| ProKidney Corp. (PROK)vs › | $536.32M | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $540.74M | N/A |
| Evolus, Inc. (EOLS)vs › | $491.28M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $12.58, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.86 | $-0.98 – $-0.74 | 3 | n/m |
| 2027-12-31 | $-0.45 | $-0.50 – $-0.41 | 3 | n/m |
| 2028-12-31 | $-0.23 | $-0.25 – $-0.22 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
